bioRxiv Science⌕ Search

Biology subjects

Josso, V.

Publications and source records attributed to Josso, V..

2 recordsLinked to original sources

The Kinase CK1α coordinates Initiation and Termination of the cGAS-STING Pathway

The cGAS-STING pathway is an evolutionarily conserved antimicrobial defense mechanism that senses cytosolic DNA to trigger innate immune responses. cGAS and STING play dual roles in tumorigenesis, promoting antitumor immunity and cell death while fueling tumor growth and metastasis. However, the mechanisms fine-tuning this pathway remain elusive. Using proteomic approaches, we report that Casein Kinase 1 alpha (CK1) operates as a bimodal regulator of the cGAS-STING pathway. CK1 supports optimal DNA sensing by preventing the proteasomal degradation of cGAS driven by the cullin-RING ubiquitin ligase 3 (CRL3). Conversely, CK1 facilitates STING degradation and signaling termination in response to STING agonists, tempering IRF3 activation. Exploiting these counterposing functions, we show that selective degradation of CK1 with molecular-glue degraders impaired the survival of a triple-negative breast cancer cell line with chronic cGAS-STING activation and synergized with a STING agonist to kill acute myeloid leukemia cells. Thus, CK1s dual regulatory role in the cGAS-STING pathway presents a promising target for therapeutic development. TEASERThis study unveils CK1 as a bimodal regulator of the cGAS-STING pathway.

immunology↗

Antimitotic chemotherapy promotes tumor NF-kB secretory phenotype and immunosuppressive CXCR2+ neutrophils chemotaxis in triple-negative breast cancers

Integrated approaches that help understand how tumors, as immune-surveilled ecosystems, respond to chemotherapy are crucial for developing effective antitumor treatments. We previously showed, in immunodeficient context, that antimitotic chemotherapy induced cGAS/STING pathway amplifying antitumor response through a paracrine IFN-1 secretome. We herein studied tumor progression and response to treatment using an immunocompetent murine model. scRNAseq analysis revealed that paclitaxel treatment altered tumor cell phenotypes, favoring tumor cells with a gene expression signature indicative of active NF-{kappa}B pathway with secretory phenotype. Treatment coincidently reduced IFN-I signature cells during tumor progression. The resulting secretory shift correlated with neutrophil recruitment to the tumor, particularly CXCR2+ neutrophils, thereby contributing to an immunosuppressive microenvironment. Pharmacological inhibition of CXCR2 receptor by navarixin reactivated antitumor immunity, enhancing NK cell infiltration and tumor cytotoxicity. Navarixin combination with paclitaxel significantly reduced tumor volume and metastasis. Targeting the NF-{kappa}B-driven secretory phenotype, in particular through neutrophil modulation, holds promise for improving TNBC treatment outcomes.

cancer biology↗